JMP Securities Maintains Market Outperform on Syros Pharmaceuticals, Lowers Price Target to $15

Benzinga · 05/11/2023 06:58
JMP Securities analyst Jason Butler maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Market Outperform and lowers the price target from $16 to $15.